The diagnostic ability for hepatic steatosis using ultrasound attenuation imaging as reference standerd MRI-PDFF, liver tissue and controlled attenuation parameter(CAP); a prospective multicenter study.

The diagnostic ability for hepatic steatosis using ultrasound attenuation imaging as reference standerd MRI-PDFF, liver tissue and controlled attenuation parameter(CAP); a prospective multicenter study. - The diagnostic ability for hepatic steatosis using ultrasound attenuation imaging as reference standerd MRI-PDFF, liver tissue and controlled attenuation parameter(CAP); a prospective multicenter study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048672

Enrollment

1000

Registered

2022-08-16

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic liver disease Patients who underwent ATI and MRI-PDFF or CAP or liver biopsy within 1 month Patients who can follow instructions such as breath-holding

Exclusion criteria

Exclusion criteria: In patients who underwent MRI-PDFF, patients with claustrophobia patients with magnetic substance or tattoo patients with pacemakers Patients judged as inappropriate for the study by the study responsibility (share) physician.

Design outcomes

Primary

Measure	Time frame
The diagnostic ability for the hepatic steatosis using ultrasound attenuation imaging	—

Countries

Japan

Contacts

Public ContactTakashi Nihsimura

Hyogo Medical University Department of Internal medicine,Division of Gastroenterology/Ultrasound Imaging Center

tk-nishimura@hyo-med.ac.jp0798-45-6472

Outcome results